

Quralis™

Driving scientific breakthroughs into powerful precision medicines for ALS and other neurodegenerative diseases

April 2026

Driving scientific breakthroughs into powerful precision medicines




Groundbreaking science

Next-gen precision medicines developed by leveraging **human disease models** pioneered by QurAlis founders

Proprietary FlexASO® platform enables precise RNA restoration in genetic diseases resulting from mis-splicing targets

Utilizing **biomarkers** for patient selection, target engagement, and efficacy



First & best-in-class programs

Lead program (QRL-201) expected to initiate pivotal study in sporadic ALS in 2027

Two additional first-in-class clinical programs for sporadic ALS **on novel genetic targets**

Expansion to **additional CNS indications** where FlexASO® technology can be applied to breakthrough biology



World-class team to execute

Seasoned executive team responsible for development of multiple approved medicines

Strong track record of execution across clinical & preclinical pipeline

UNC13A partnership with Lilly highlights value of FlexASO® platform

QurAlis' expertise and technologies enable two distinct franchises

Pursuing treatment for CNS disorders with innovative biology and proven modalities

RNA Restoration

(antisense oligonucleotide, "ASO")

- Potential to develop first-in-class and best-in-class medicines utilizing FlexASO[®] platform
 - Two active ASO candidates currently in clinical trials (QRL-201, QRL-204)
- Specifically addresses mis-splicing targets which underly biology of neurodegenerative diseases including:
 - TDP-43-opathies
 - Tau-opathies
 - Fragile X syndrome
- Multiple candidates generated to date with reproduceable path to IND and Proof of Concept (PoC)

Ion Channel Recovery

(small molecule)

- Kv7.2/7.3 potassium channel is a commercially or clinically validated target for multiple high unmet need indications, including:
 - Epilepsy (focal, generalized, DEEs, etc.)
 - Pain (acute, neuropathic, etc.)
 - >50% of ALS
 - Mood disorders
- QRL-101, a highly selective Kv7.2/7.3 opener, is well positioned as potential best-in-class therapeutic:
 - Developed in partnership with Eli Lilly; full global rights licensed to QurAlis
 - High selectivity results in lack of burdensome side effects associated with first-generation Kv7 compounds
 - Formulations optimized for different indications

Advancing precision neuroscience pipeline across multiple clinical and preclinical programs

Program	MOA	Indication	Upcoming Milestone(s)	Discovery	IND-Enabling	Ph1 Safety / PoM ¹	Proof of Concept	Registration Studies
QRL-201	STMN2	ALS	PoC ³ transitioning to OLE, pivotal study initiation expected 2027					
QRL-101	Kv7.2/7.3	DEEs ²	KCNQ2 PoC ³ initiation H2 2026 ⁴					
		ALS	PoC ³ planning under way					
QRL-204	UNC13A	Pain	PoM ¹ study initiation H2 2026 ⁴					
		ALS / FTD	In partnership with <i>Lilly</i>					
QRL-TBA	FMR1	Fragile X	DC ⁵ nomination 2026					
QRL-TBA	Undis.	PSP	DC ⁵ nomination 2026					

1. PoM = Proof of Mechanism; 2. DEE = Developmental and Epileptic Encephalopathy; 3. PoC = Proof of Concept; 4. Pending Series C funding; 5. DC = development candidate


Pioneers with unrelenting commitment to patients



Kasper Roet,
PhD
CEO
Co-founder



Guzide Adhikari,
PhD
SVP CMC
Operations &
Strategy



Jason Brown,
MBA
CFO & COO



Hagen Cramer,
PhD
CTO



Dan Elbaum,
PhD
CSO



Manoj Malhotra
MD
CMO



Vikas Sharma,
PhD
CBO



Supported and recognized by investors, pharma, and industry



Investors



EQT
Life Sciences

sanofi ventures



DROIA ventures



**Dementia
Discovery
Fund**

inkef capital



MP Healthcare Venture Management, Inc.
Mitsubishi Tanabe Pharma Group



ALEXANDRIA



Awards



FIERCE 15
2020 WINNER



THE
TERMEER
FOUNDATION



Collaborators



*QRL-101 in-license
QRL-204 out-license*



**UMass Chan
MEDICAL SCHOOL**

Fragile X

RNA Restoration: STMN-2 Program



QurAlis is pioneering novel genetic treatments for ALS

ALS is a devastating neurodegenerative disease with significant unmet medical need




220,000+
global prevalence (est.)


2-3
months

Current approved therapies (riluzole, edaravone) only provide modest survival benefit


+25% Increase in prevalence expected by 2040



Every **90** Minutes someone is diagnosed with ALS, and someone passes away from it



■ TDP-43 pathology (sporadic, C9orf72)
■ Non-TDP-43 pathology (SOD-1, FUS)



\$250,000
Estimated annual out-of-pocket cost for care

QRL-201: STMN2-targeting ASO for treatment of sporadic ALS

STMN2 is the most consistently downregulated gene in sporadic ALS patients

- STMN2 is most strongly down-regulated by TDP-43 mis-localization
- Restoration of STMN2 pre-mRNA mis-splicing through ASO treatment restores neuronal processes, Golgi outposts, and protects neuronal activity in human motor neurons
- Two approved ASO therapies for motor neuron diseases (Spinraza® for SMA and Qalsody® for SOD-1 ALS) demonstrate that an ASO therapy strategy to restore STMN2 in ALS patients is technologically feasible



- ANQUR results demonstrated effects on disease progression and target engagement in sporadic ALS population
 - Confirmed target engagement through tissue analysis
 - Statistically significant impact on neurofilament biomarker (pNfH)
 - Post-hoc sub-group analysis shows statistically significant effect on ALSFRS-R
- Pivotal study expected to initiate in 2027
- QurAlis retains full global rights; CoM patent through 2040 plus potential PTE, pending issuance


Restoration of STMN2 levels by ASO is a promising therapeutic strategy for the majority of ALS patients

QRL-201 restores full-length STMN2 and protects neurons from degeneration phenotypes

Breakthrough discovery shows TDP-43 driven neurodegenerative phenotypes caused by STMN2 loss


Loss of TDP-43 from the nucleus (ALS hallmark) leads to loss of STMN2

TDP-43 loss causes loss of axons; rescue by restoring STMN2 levels




- Melamed Z, López-Erauskin J, Baughn MW, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. *Nat Neurosci*. 2019;22(2):180-190. doi:10.1038/s41593-018-0293-z
- Klim, J.R., Williams, L.A., Limone, F. et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. *Nat Neurosci* 22, 167–179 (2019). <https://doi.org/10.1038/s41593-018-0300-4>
- Baughn, M. W., et al. (2023). "Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies." *Science* 379(6637): 1140-1149.
- Krus et al., 2022 *Cell Rep* Jun 28;39(13):111001. doi: 10.1016/j.celrep.2022.111001


STMN2 is downregulated in ALS patients



Loss of STMN2 leads to denervation of muscles



QRL-201 restores STMN2



QRL-201 restores neuronal processes



TDP-43 Pathology




TDP-43 Pathology +QRL-201 (STMN2 Rescue)

ANQUR proof-of-concept Phase 1/2 design overview

Progressed from MAD¹ to DRF² phase based on positive PK & tolerability in MAD cohorts


MAD (dose escalation) phase



MAD (dose escalation) phase details

- Total of 17 sporadic patients (randomized ~3:1) with broad inclusion criteria enrolled and treated with QRL-201 or placebo for three months
- DSMB recommended continuing with dosing after both cohorts
- Higher than expected CSF exposures from NHP model, with first cohort exceeding estimated efficacy threshold by ~10-fold
- Half-life estimated to exceed 100 days, providing opportunity to test signal detection given >95% of patients expected to be above estimated efficacy threshold for ~9 months, including in DRF low dose group

DRF phase



DRF phase details

- Total of 52 patients (37 sporadic, 15 C9orf72) enrolled and treated with QRL-201 or placebo for 3 months
- Tightened inclusion criteria (<24 months from diagnosis, evidence of lower motor neuron involvement) to homogenize patient population
- High dose set equivalent to MAD Cohort 1 given CSF PK & half-life observed
- Expanded collection biomarker & clinical efficacy measurements beyond dosing period to inform dose response and potentially identify responder population

¹ MAD = Multiple Ascending Dose

² DRF = Dose-Range Finding

ANQUR summary of results

Consistent improvement across multiple endpoints and translation from preclinical data

QRL-201 was generally safe and well tolerated; Data Safety Monitoring Board (DSMB) agreed to continue the study without modifications during all phases, and as recently as December 2025

Target engagement confirmed through post-mortem tissue analysis

- Broad distribution across the spinal cord and motor cortex
- Statistically significant increased levels of STMN2 (above the estimated therapeutic target) and correction of STMN2 mis-splicing¹

A statistically significant and clinically meaningful reduction in pNfH² in the low dose group compared to placebo

An encouraging trend of slowing decline in ALSFRS-R in sporadic patients in DRF phase

- Strong trend on the gross motor sub-score, which is critical for patient independence
- In a post-hoc analysis excluding patients with higher levels of baseline neurofilament light, which is associated with faster disease progression, there was a statistically significant and clinically meaningful slowing of decline in ALSFRS-R at the 6-months (24-weeks) timepoint in treated sporadic ALS patients compared to placebo
- C9orf72 patient cohort was inconclusive as both baseline ALSFRS-R and NfL were materially un-balanced, analysis on-going

Pharmacokinetics & target engagement are supportive of biomarker and clinical efficacy observations

Pharmacokinetics (PK)

- ☑ Dose-proportional uptake observed in CSF¹
- ☑ Half-life estimated to exceed 100 days, providing opportunity for less frequent dosing in future studies
- ☑ All doses tested were well in excess of estimated efficacy threshold. Low-dose PK median concentration after last dose is estimated to be 6-fold above estimated efficacy threshold
- ☑ Autopsy sample analysis indicated relatively homogeneous tissue distribution of QRL-201 throughout spinal cord and motor cortex

Target Engagement


- Autopsy samples were obtained from the MAD phase of the study²
- mRNA tissue analysis was performed using validated assays and compared to natural history ALS patient controls, dosing with QRL-201 showed:
 - ☑ Statistically significant increase of STMN2 full length levels in spinal cord above estimated therapeutic target
 - ☑ Statistically significant improvement of the ratio of full length STMN2 full to cryptic STMN2 levels in the spinal cord (splice correction)
 - ☑ No measurable cryptic STMN2 levels in the motor cortex

¹ CSF = Cerebrospinal fluid

² Patient samples were obtained within 6 months after their last dose

Clinically meaningful reduction in pNfH compared to baseline and placebo

pNfH in CSF¹, Change from Baseline
MAD & DRF Phases Combined²



Key Findings

- Statistically significant result in low-dose group at 2 months (Day 57) and 4 months (Day 113) with >40% average reduction
- All patients in low-dose group were lower than baseline at Day 113
- High-dose group did not achieve statistical significance, but does represent nearly 20% reduction

P<0.05: *

	Day 1	Day 29	Day 57	Day 85	Day 113
QRL-201 - High Dose	30	29	29	27	20
QRL-201 - Low Dose	12	11	12	11	8
Placebo	16	15	15	12	9


Group	% (N) vs. baseline at Day 113	
	Lower	Higher
Placebo	55% (5)	45% (4)
Low Dose	100% (8)	0% (0)
High Dose	85% (17)	15% (3)
Total Treated	89% (25)	11% (3)

¹CSF = Cerebrospinal Fluid

²All enrolled patients, including *C9orf72* patients but excluded MAD Cohort 2 Treatment Group, which was at a dose level higher than the High Dose in DRF phase

Trend of positive effect on ALSFRS-R in sporadic low dose and high dose DRF compared to placebo

ALSFRS-R Total Score, Change from Baseline
Sporadic ALS, DRF Phase¹



Key Findings

- Slowing of ALSFRS-R decline observed on numerical basis, even with small patient numbers
- Baseline values were 39.6 for QRL-201 and 39.8 for placebo
- Similar results observed in both dose groups
- Most pronounced effect observed in the gross motor sub score, which is critical for patient independence

QRL-201	27	26	27	27	26	-2	20	16
Placebo	10	10	10	10	10	-2	5	3

¹Includes QRL-201 treated sporadic ALS patients (excludes C9orf72 patients) from low & high dose DRF groups pooled into single treatment group


²No measurement taken at Day 141 (~5 months)

High NfL baseline identifies fast progressing ALS patients and can be used for patient stratification

Fast progressing patients have high baseline NfL and can provide challenges in clinical trials

- NfL has been known to correlate with the rate of disease progression¹
- In ANQUR, no inclusion criteria were applied to select for baseline NfL levels, and there was a >10-fold intersubject difference in baseline values
 - Tertiles (thirds) were stratified for all patients in ANQUR study to determine whether there was a correlation between ALSFRS-R response and baseline NfL
- In post-hoc analysis, ANQUR study demonstrated statistically significant separation in sporadic population at Day 169 (6 months) when excluding fast-progressing subgroup, as defined by patients in the highest tertile of NfL at baseline

Baseline values correlate with survival




¹ Benetar et al. 2024. Legend for Panel C: Kaplan-Meier survival curves (Permanent-assisted ventilation / tracheostomy-free survival) for quartiles of NfL baseline

Statistically significant separation of ALSFRS-R in sporadic patients at 6 months excluding high tertile NfL patients

Post-hoc analysis excludes highest third of baseline NfL which correspond to fast progressors

ALSFRS-R Total Score, Change from Baseline
Sporadic ALS
Excluding Highest Tertile NfL at Baseline¹



Key Findings

- Statistically significant result at 6 months (24 weeks) with strong trend emerging as early as 4 months (16 weeks)
- Baseline values were 40.2 for QRL-201 and 39.5 for placebo
- Most pronounced effect observed in the gross motor sub score, which is critical for patient independence
- Low dose group showed more robust response

P<0.05: *

QRL-201	22	22	22	22	22	-2	12	10
Placebo	10	10	9	9	9	-2	4	3

¹Includes QRL-201 treated sporadic ALS patients across MAD and DRF phases (excludes C9orf72 patients) from low & high dose groups combined into single treatment group, excluding patients that were the highest one-third of baseline neurofilament light (NfL) values. Patients from MAD phase did not have measurements beyond Day 113 (~4 months)


²No measurement taken at Day 141 in any group (~5-months)

QRL-201 ANQUR trial data summary key take-aways

STMN2 is the most consistently downregulated gene in sporadic ALS leading to loss of function & QRL-201 restores STMN2 levels



QRL-201 was generally safe and well tolerated



Target engagement and broad distribution in relevant brain & spinal cord areas confirmed through post-mortem tissue analysis



A statistically significant and clinically meaningful reduction in pNfH in the low dose group compared to placebo



An encouraging trend of slowing decline in ALSFRS-R in sporadic patients

ANQUR study is transitioning to an open-label extension (OLE) phase
Pivotal planning is under way with study expected to initiate in 2027

QRL-101 Epilepsy Program



Ion channel dysfunction is implicated across wide range of CNS disorders

Kv7.2/3 channel openers have validation across variety of diseases



- GSK's ezogabine was marketed for partial-onset seizures
- Flupirtine was also approved in Europe for 6 different pain indications
- Kv7.2/3 in epilepsy has been demonstrated by azetukalner and other clinical programs



Older generation Kv7 ion channel openers exhibited safety & adverse event liabilities due to:

- Non-specific binding
- GABA-A affinity




- QurAlis' QRL-101 is a highly selective Kv7.2/3 channel opener:
 - High affinity to Kv7.2/3
 - Lack of affinity for GABA-A receptors and other Kv7 subtypes
 - Human target engagement observed in Phase 1 studies relevant for epilepsy, pain and ALS

Approved therapies constitutes 5 DEE type - number of “other” DEEs is a significant market opportunity

Improved genetic diagnosis, high refractory rates, polypharmacy further expand the commercial opportunity

7MM Distribution of Developmental & Epileptic Encephalopathies (DEEs)



NO APPROVED THERAPIES FOR “Other” DEEs

- DUP15q Syndrome
- SCN2A-DEE
- SCN8A-DEE
- **KCNQ2-DEE**
- **KCNQ3-DEE**
- Angelman Syndrome
- Landau-Kleffner Syndrome
- Early Myoclonic Encephalopathy
- KCNT1-DEE
- SynGAP1-DEE
- Ohtahara Syndrome
- PCDH19
- EE w/ Continuous Spike-Wave
- Myoclonic Atonic Epilepsy
- Ring14
- Ring20
- Others

~4,000 US patients¹

1. U.S. registry & genetic testing data (Mullen SA et al., Neurology 2018; Millichap JJ et al., Epilepsia 2020; Invitae cohort 2023)
 2. Estimated diagnosed prevalent DEE patients in the 7MM (US, EU4/UK, Japan). Directional estimates synthesized from published epidemiology and industry analyses. “Other DEEs” represent heterogeneous genetic/structural DEEs without FDA-approved, subtype-labeled therapies.
 3. DelveInsight/Research & Markets reports
 4. Other DEE % calculated based on currently available information, however the % is higher than reported as reported by other companies
 5. Definitions: LGS = Lennox-Gastaut Syndrome, CDD = CDKL5 Deficiency Disorder, TSC = Tuberous Sclerosis Complex; DEE = Developmental and Epileptic Encephalopathy

Robust Phase 1 data package supports future development

QRL-101 has been dosed in 163 subjects to date¹

Phase 1 clinical package

Tolerability, Safety & PK (Liquid Formulation):

HV SAD (N=88) & HV MAD (N=60)

Central & Peripheral Target Engagement:

HV Proof of Mechanism (N=27)

Target Engagement in ALS Patients:

Proof of Mechanism (N=12)

Tolerability, Safety & PK (SDD formulation):

HV SAD (N=25)

Safety, Tolerability & PK Findings

- Generally well tolerated, large majority of AEs were mild & transient
- No treatment-emergent SAEs observed across any study
- New formulation demonstrates a significantly lower peak-to-trough ratio and AEs as compared to liquid formulation

Target Engagement Findings

- **Epilepsy (central):**
 - Statistically significant results on TMS-Evoked Potential
 - Statistically significant Passive EEG high-frequency gamma & beta bands
 - No effect on Passive EEG low-frequency bands associated with sedation
 - Statistically significant reduction in TMS-EMG intracortical facilitation
- **ALS / Pain (peripheral):**
 - Several measures of peripheral nerve excitability demonstrated inhibitory effects, including multiple measures with dose dependent response
 - Consistent results observed in both ALS patients & healthy volunteers

¹As of December 31, 2025


HVs: Healthy Volunteers; SAD: Single Ascending Dose; MAD: Multiple Ascending Dose; PoM: Proof of Mechanism; PK: Pharmacokinetics

QRL-101 shows inhibition in TEP measurements even at the low dose of the PoM study

QRL-101-05 study evaluated multiple biomarkers relevant for CNS target engagement in 27 healthy volunteers in a three-way crossover study:


- ☑ **TMS-Evoked Potential** (pictured right) low dose demonstrated statistically significant reductions vs. placebo at both timepoints
- ☑ **Passive EEG** demonstrated statistically significant effects on high-frequency beta & gamma bands associated with anti-seizure activity, while not having impact on low-frequency delta & theta bands associated with sedation
- ☑ **TMS-EMG** showed statistically significant changes in intracortical facilitation (ICF), measuring the effect on inhibition / excitability ratio

TMS Evoked Potential Results



Aktiva7e KCNQ2 epilepsy trial design

Initiation expected H2 2026



DESIGN	Randomized, double-blind, placebo-controlled trial
POPULATION	Subjects 12-65 years of age with Ultra Rare Epilepsy (KCNQ2) Loss of Function (LoF)
SAMPLE SIZE	n=9, randomized 2:1 (QRL-101:PBO)
KEY ENTRY CRITERIA	Age 12-65 and diagnosed with KCNQ2 having >2 seizures/month
ENDPOINTS	Safety and tolerability



**Administered as a BID extended-release granules (SDD)*

QRL-101 Expansion Opportunities





KCNQ2 mis-splicing in ALS with TDP-43 pathology

RNA mis-splicing of the voltage gated potassium channel KCNQ2 is a key hallmark of ALS related TDP-43 proteinopathy




KCNQ2 is one of the top mis-spliced RNAs in TDP-43 depleted motor neurons in ALS postmortem tissue
(Held et al 2021, Joseph et al 2025)




KCNQ2 mis-splicing accelerates motor neuron disease

Promotes hyperexcitability, motor neuron death and accelerates ALS disease progression

Healthy




Nuclear TDP-43
Normal KCNQ2 function




Normal neuronal activity

DAPI / KCNQ2
MAP2 / ANK




Functional KCNQ2

ALS




TDP-43 loss of function
KCNQ2 RNA mis-splicing




Hyperexcitability

DAPI / KCNQ2
MAP2 / ANK




Mislocalized, Dysfunctional KCNQ2

Motor neuron hyperexcitability is correlated with accelerated ALS disease progression
(Kanai et al 2012)



Ezogabine has been shown to improve motor neuron survival




(Shi et al 2019)


Clinical impact of Kv7 on hyperexcitability in ALS was first demonstrated by the first-generation Kv7 ezogabine¹

Small investigator-led study demonstrated meaningful impact on disease progression biomarkers

Statistically significant² dose-dependent effects on biomarkers that predict patient survival



Statistically significant² impact on critical disease progression & efficacy biomarker (CMAP)



Nearly all (97%) participants in the trial reported at least one adverse event
Most frequent adverse events among participants in the ezogabine arms were fatigue and dizziness


¹Wainger BJ, Macklin EA, Vucic S, et al. *JAMA Neurol.* 2021;78(2):186–196. doi:10.1001/jamaneurol.2020.4300

²Error bars (directly from JAMA) represent standard deviations, results are statistically significant

Compelling QRL-101 results on hyperexcitability biomarkers in both ALS patients and healthy volunteers


Evaluating next steps of development

Retigabine statistically significantly¹ reduced SDTC, a biomarker predictive of patient survival




- N=18 ALS patients
- Single dose cross-over study at Utrecht, each compared to self on placebo
- Treatment v. placebo effect p=0.001

QRL-101 reduces SDTC in a dose dependent manner in healthy and ALS patients. The window of effect is larger in ALS



- N=3/group ALS patients
- Single dose study at Utrecht, placebo group is unique individuals



- N=26 / group healthy volunteers
- Single dose cross-over study at CHDR, each compared to self on placebo
- Treatment v. placebo effect p=<0.0001

Kv7 channel activation to treat pain: A proven therapeutic strategy

Chronic pain affects tens of millions—and existing options fall short


- **More than 20% of U.S. adults** reported experiencing chronic pain (pain lasting three months or more) in the past 3 months¹
 - **8.5% of adults reported high-impact chronic pain** — pain that frequently limits life or work activities¹
- Neuronal hyperexcitability is a central driver of pain
 - **Kv7 channels tightly regulate sensory neuron firing**, controlling pain signal initiation
 - Function as a **voltage clamp**, preventing small depolarizations from triggering aberrant pain signals
- Clinical validation of the mechanism
 - **Flupirtine, a Kv7 opener, demonstrated broad analgesic efficacy** (neuropathic, post-operative, back pain, headache, dysmenorrhea and others)
 - Used for **>20 years in Europe**, withdrawn due to hepatic toxicity with chronic use—*not lack of efficacy*
- Potential to deliver **effective pain relief without the limitations of current standards of care**

¹ Centers for Disease Control & Prevention (CDC)

Exploratory Phase 1 induced-pain study planned to investigate analgesic effects of QRL-101

PainCart® proof-of-mechanism study expected to initiate in H2 2026

- Kv7 opener flupiritine was prescribed for 6+ indications in multiple European countries, before being withdrawn from the market due to hepatic toxicity in chronic use
- PainCart® is designed for indication selection through testing multiple different modalities, physiology, and leveraging quantitative and qualitative outcome measures
 - Models: cold pressor, electrical stimulation, pneumatic pressure, conditional pain modulation, thermal stimulation, UV-B model, capsaicin model
 - Three-way cross-over design with placebo, low and high dose, utilizing SDD formulation to further characterize PK / PD profile
- Provides unique profile which can be compared to existing treatments:



QRL-101 key take-aways



Multiple Kv7 ion channel openers have shown signals of efficacy in epilepsy, pain, ALS



Off-target liabilities associated with past generation Kv7 agonists resulted in commercial limitations and market withdrawals



QRL-101 is an ultra-selective Kv7.2/3 channel opener that exhibits superior selectivity profile


163 subjects dosed till date



Human target engagement observed in Phase 1 studies relevant for epilepsy, pain and ALS

QurAlis preparing to initiate PoC study in KCNQ2-DEE

Potential for positive outcomes in DEEs, pain and ALS differentiating QRL-101 from competitors and presents a global commercial opportunity



RNA Restoration: FlexASO[®] Platform

FlexASO[®] delivers powerful combination of therapeutic benefits

FlexASO[®] Architecture

- ✓ **Novel backbone design:** Sugar-backbone modification unlocks structural flexibility
- ✓ **Optimized architecture:** ASO length and location of Flex modifications tuned for target
- ✓ **Controlled hybridization:** These modifications additionally reduce off-target hybridization

Therapeutic Advantages



Greater Therapeutic Potency

Enables superior splicing correction, ensuring more robust target engagement and functional RNA restoration.



Enhanced Precision & Safety

Minimizes off-target effects, reducing toxicity, immune activation, and unintended gene regulation.



Prolonged Therapeutic Effects & Less Frequent Dosing

Optimizes CNS biodistribution, reaching deep-layer degenerative neurons for sustained therapeutic impact.

Genetic understanding of diseases and tech breakthroughs generate opportunity to develop RNA restoration therapies

Technological breakthroughs




Patient-derived human disease models increase probability of success



Technology to potentially support 2x / year dosing has been developed (e.g., FlexASO[®] tech.)



Technology to cross blood-brain-barrier has matured (e.g., transferrin receptor)



RNA restoration oligonucleotides targets

Diseases caused by mis-splicing (e.g., SMA, ALS, FTD, Fragile X, PSP)



Diseases caused by haploinsufficiency (e.g., Dravet)



Previously undruggable targets for large indications





QuralisTM

Thank you

For more information contact:
Kasper Roet (CEO & Cofounder)
kasper.roet@quralis.com

Jason Brown (CFO & COO)
jason.brown@quralis.com

Advised by leading clinicians and scientists in neurodegeneration field

CAB



Angela Genge (Chair)
MB, FRCP



Ammar Al-Chalabi
MB, ChB, PhD



Merit Cudkowicz
MD, MSc



Dame Pamela J. Shaw
DBE, MBBS, MD,
FRCP, FMedSci,
FAAN, FANA, FAAS



Philip Van Damme
MD, PhD



Leonard van den Berg
MD, PhD



Amy Chappell
MD, FAAN



SAB



Clifford Woolf
MD, PhD



Kevin Eggan
PhD



Matthew Kiernan
MD, PhD



Bernhardt Trout
PhD



Brian Wainger
MD, PhD



Christopher Shaw
MD, PhD



Sudhir Agrawal
PhD



Michelle Hastings
PhD

